Life-Changing Medicines.
Redefining Possibilities.
Jazz Pipeline
PRE-CLINICAL
Oxybate
once-nightly dosing
CombiPlex
Solid tumors

CombiPlex
Hematological malignancies

Asparaginase
ALL/other hematological malignancies
Recombinant pegaspargase
Hematological
malignancies
Defibrotide
Exploratory activities

Exosome NRAS
Hematologic malignancies§

Exosome STAT3
Hematologic malignancies§

Exosome candidates
Solid tumors/Hematologic malignancies§

PHASE 1
CPX-351 + gemtuzumab
R/R AML or HMA Failure
MDS* (ages ≥18)

CPX-351 + venetoclax
Low intensity dosing for unfit AML†

IMGN779
R/R CD33+ AML

IMGN632
CD123+ hematological malignancies

PHASE 2
Solriamfetol
EDS in Parkinson’s disease
Defibrotide
Prevention of acute GvHD
Defibrotide
Treatment of TA-TMA†
Defibrotide
Prevention of CAR-T associated neurotoxicity†

CPX-351 + venetoclax
de novo or R/R AML*

CPX-351
MDS**†

CPX-351
R/R AML**

PHASE 3
JZP-258
Cataplexy & EDS in narcolepsy

JZP-258
idiopathic hypersomnia

Defibrotide
Prevention of VOD

CPX-351
AML or HR-MDS (AML19) (ages 18-60)**‡

CPX-351
AML or HR-MDS (AML18) (ages ≥60)**‡

REGULATORY
Solriamfetol EU
EDS in OSA or narcolepsy
Solriamfetol U.S.
EDS in OSA and narcolepsy

Sleep
Hematology / Oncology
Opt-in Opportunity
*Jazz & MD Anderson Cancer Center Study
** Key Cooperative Group Study
Planned
Study Sponsor – Cardiff University
§Jazz & Codiak BioSciences collaboration
Jazz & ImmunoGen collaboration

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
Living Our Values

Careers at Jazz

Clinical Trials

Learn More

By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.